5-alpha reductase inhibitors and MRI prostates: actively reducing prostate sizes and ambiguity.
Ziting WangKaiying WangHan Yang OngWoon Chau TsangQing Hui WuEdmund ChiongPublished in: BMC urology (2023)
Our study found significant differences in biochemical, imaging and biopsy characteristics between 5-ARI and non-5-ARI groups. While both groups had similar PIRADS distribution, 5-ARI patients had a lower rate of positive biopsies across all PIRADS categories, which may suggest that the use of 5ARI may confound MRI findings. Further studies on how 5-ARI therapy affects the imaging characteristics of prostate cancer should be performed.
Keyphrases
- prostate cancer
- magnetic resonance imaging
- high resolution
- end stage renal disease
- contrast enhanced
- ejection fraction
- benign prostatic hyperplasia
- prognostic factors
- diffusion weighted imaging
- ultrasound guided
- computed tomography
- mesenchymal stem cells
- fine needle aspiration
- cell therapy
- case control
- patient reported
- stem cells
- replacement therapy